Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.
Protein

Basic phospholipase A2 homolog bothropstoxin-1

Gene
N/A
Organism
Bothrops jararacussu (Jararacussu)
Status
Reviewed-Annotation score: Annotation score: 5 out of 5-Experimental evidence at protein leveli

Functioni

Snake venom phospholipase A2 homolog that lacks enzymatic activity. In vivo, induces muscle necrosis, accompanied by polymorphonuclear cell infiltration, and edema in the mouse paw. Damages artificial and myoblast membranes by a calcium-independent mechanism. Has bactericidal activity.7 Publications

GO - Molecular functioni

GO - Biological processi

Complete GO annotation...

Keywords - Molecular functioni

Antibiotic, Antimicrobial, Myotoxin, Toxin

Names & Taxonomyi

Protein namesi
Recommended name:
Basic phospholipase A2 homolog bothropstoxin-1
Short name:
svPLA2 homolog
Alternative name(s):
BOJU-I
Bothropstoxin I
Short name:
BthTx-I
Short name:
BtxtxI
Myotoxic phospholipase A2-like
Phospholipase A2 homolog 1
OrganismiBothrops jararacussu (Jararacussu)
Taxonomic identifieri8726 [NCBI]
Taxonomic lineageiEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiLepidosauriaSquamataBifurcataUnidentataEpisquamataToxicoferaSerpentesColubroideaViperidaeCrotalinaeBothrops

Subcellular locationi

GO - Cellular componenti

Complete GO annotation...

Keywords - Cellular componenti

Secreted

Pathology & Biotechi

Toxic dosei

LD50 is 7.5-8.5 mg/kg by intraperitoneal injection and 4.8 mg/kg by intravenous injection into mice.2 Publications

Mutagenesis

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Mutagenesisi23 – 231K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi31 – 311K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi51 – 511K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi52 – 521P → A: Important decrease in myotoxicity when injected into mice. Decrease in membrane permeabilization of cultured myoblasts. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Increase in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi53 – 531K → A: No change in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. No change in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi54 – 541D → A: No change in myoblast membrane permeabilizing activities. 1 Publication
Mutagenesisi58 – 581R → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi61 – 611Y → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi63 – 631H → Q: No change in myotoxic activities. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent membrane-damaging activities. Shows no hydrolytic activity. 3 Publications
Mutagenesisi64 – 641K → D: No change in myotoxic activities. No change in calcium-independent membrane-damaging and myotoxic activities. Shows no hydrolytic activity. 1 Publication
Mutagenesisi68 – 681K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi69 – 691K → A: Increase in myotoxicity when injected into mice. Increase in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi71 – 711T → KR: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes.
Mutagenesisi87 – 871K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi93 – 931E → G: No change in myotoxicity when injected into mice. Important decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi99 – 991K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi106 – 1061K → A: Increase in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi118 – 1181T → A: No change in myoblast membrane permeabilizing activities. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi120 – 1201N → A: No change in myotoxicity when injected into mice. Increase in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi121 – 1211K → A: No change in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications
Mutagenesisi122 – 1221K → A: No change in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications
Mutagenesisi123 – 1231Y → A: Important decrease in myotoxicity when injected into mice. Important decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications
Mutagenesisi123 – 1231Y → W: No change (PubMed:17346668) or important decrease (PubMed:12079495) in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Important increase in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications
Mutagenesisi124 – 1241R → A: Important decrease in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications
Mutagenesisi125 – 1251Y → A: Important decrease in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications
Mutagenesisi125 – 1251Y → W: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications
Mutagenesisi126 – 1261H → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi127 – 1271L → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication
Mutagenesisi128 – 1281K → A: Important decrease in myotoxicity when injected into mice. Important decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. Shows no hydrolytic activity. 4 Publications
Mutagenesisi130 – 1301F → A: Important decrease in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications
Mutagenesisi130 – 1301F → W: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease (PubMed:17346668) or important decrease (PubMed:12079495) in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications
Mutagenesisi132 – 1321K → A: No change in myotoxicity when injected into mice. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications
Mutagenesisi133 – 1331K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications

PTM / Processingi

Molecule processing

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Signal peptidei1 – 16163 PublicationsAdd
BLAST
Chaini17 – 137121Basic phospholipase A2 homolog bothropstoxin-1PRO_0000161622Add
BLAST

Amino acid modifications

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Disulfide bondi42 ↔ 131Combined sources3 Publications
Disulfide bondi44 ↔ 60Combined sources3 Publications
Disulfide bondi59 ↔ 111Combined sources3 Publications
Disulfide bondi65 ↔ 137Combined sources3 Publications
Disulfide bondi66 ↔ 104Combined sources3 Publications
Disulfide bondi73 ↔ 97Combined sources3 Publications
Disulfide bondi91 ↔ 102

Keywords - PTMi

Disulfide bond

Expressioni

Tissue specificityi

Expressed by the venom gland.

Interactioni

Subunit structurei

Homodimer; non-covalently linked.3 Publications

Structurei

Secondary structure

1
137
Legend: HelixTurnBeta strand
Show more details
Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Helixi18 – 2912Combined sources
Helixi33 – 375Combined sources
Beta strandi38 – 403Combined sources
Turni41 – 433Combined sources
Beta strandi44 – 474Combined sources
Helixi55 – 6713Combined sources
Turni75 – 773Combined sources
Beta strandi82 – 854Combined sources
Beta strandi88 – 914Combined sources
Helixi96 – 11419Combined sources
Helixi116 – 1183Combined sources
Helixi121 – 1233Combined sources
Helixi128 – 1303Combined sources

3D structure databases

Select the link destinations:
PDBei
RCSB PDBi
PDBji
Links Updated
EntryMethodResolution (Å)ChainPositionsPDBsum
2H8IX-ray1.90A/B17-137[»]
3CXIX-ray1.83A/B17-137[»]
3HZDX-ray1.91A/B17-137[»]
3HZWX-ray2.28A/B17-127[»]
3I03X-ray1.48A17-137[»]
3I3HX-ray2.17A/B17-137[»]
3I3IX-ray1.82A17-137[»]
3IQ3X-ray1.55A/B17-137[»]
4K06X-ray2.08A/B17-137[»]
4K09X-ray2.11A/B17-135[»]
4WTBX-ray2.16A/B17-137[»]
ProteinModelPortaliQ90249.
SMRiQ90249. Positions 17-137.
ModBaseiSearch...
MobiDBiSearch...

Miscellaneous databases

EvolutionaryTraceiQ90249.

Family & Domainsi

Sequence similaritiesi

Keywords - Domaini

Signal

Phylogenomic databases

HOVERGENiHBG008137.

Family and domain databases

Gene3Di1.20.90.10. 1 hit.
InterProiIPR001211. PLipase_A2.
IPR033112. PLipase_A2_Asp_AS.
IPR016090. PLipase_A2_dom.
IPR033113. PLipase_A2_His_AS.
[Graphical view]
PANTHERiPTHR11716. PTHR11716. 1 hit.
PfamiPF00068. Phospholip_A2_1. 1 hit.
[Graphical view]
PRINTSiPR00389. PHPHLIPASEA2.
SMARTiSM00085. PA2c. 1 hit.
[Graphical view]
SUPFAMiSSF48619. SSF48619. 1 hit.
PROSITEiPS00119. PA2_ASP. 1 hit.
PS00118. PA2_HIS. 1 hit.
[Graphical view]

Sequencei

Sequence statusi: Complete.

Sequence processingi: The displayed sequence is further processed into a mature form.

Q90249-1 [UniParc]FASTAAdd to basket

« Hide

        10         20         30         40         50
MRTLWIMAVL LVGVEGSLFE LGKMILQETG KNPAKSYGAY GCNCGVLGRG
60 70 80 90 100
KPKDATDRCC YVHKCCYKKL TGCDPKKDRY SYSWKDKTIV CGENNPCLKE
110 120 130
LCECDKAVAI CLRENLGTYN KKYRYHLKPF CKKADPC
Length:137
Mass (Da):15,497
Last modified:July 22, 2008 - v3
Checksum:i7BE006BABC4DFC39
GO

Experimental Info

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Sequence conflicti23 – 231K → H AA sequence (PubMed:3176051).Curated
Sequence conflicti74 – 741D → N AA sequence (PubMed:8427634).Curated

Natural variant

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Natural varianti19 – 191F → L.
Natural varianti37 – 371Y → H.
Natural varianti136 – 1361P → A.

Sequence databases

Select the link destinations:
EMBLi
GenBanki
DDBJi
Links Updated
AY185200 mRNA. Translation: AAO27453.1.
AY299391 mRNA. Translation: AAP57527.1.
X78599 mRNA. Translation: CAA55334.2.
PIRiA30823.
PC4024.

Cross-referencesi

Sequence databases

Select the link destinations:
EMBLi
GenBanki
DDBJi
Links Updated
AY185200 mRNA. Translation: AAO27453.1.
AY299391 mRNA. Translation: AAP57527.1.
X78599 mRNA. Translation: CAA55334.2.
PIRiA30823.
PC4024.

3D structure databases

Select the link destinations:
PDBei
RCSB PDBi
PDBji
Links Updated
EntryMethodResolution (Å)ChainPositionsPDBsum
2H8IX-ray1.90A/B17-137[»]
3CXIX-ray1.83A/B17-137[»]
3HZDX-ray1.91A/B17-137[»]
3HZWX-ray2.28A/B17-127[»]
3I03X-ray1.48A17-137[»]
3I3HX-ray2.17A/B17-137[»]
3I3IX-ray1.82A17-137[»]
3IQ3X-ray1.55A/B17-137[»]
4K06X-ray2.08A/B17-137[»]
4K09X-ray2.11A/B17-135[»]
4WTBX-ray2.16A/B17-137[»]
ProteinModelPortaliQ90249.
SMRiQ90249. Positions 17-137.
ModBaseiSearch...
MobiDBiSearch...

Protocols and materials databases

Structural Biology KnowledgebaseSearch...

Phylogenomic databases

HOVERGENiHBG008137.

Miscellaneous databases

EvolutionaryTraceiQ90249.

Family and domain databases

Gene3Di1.20.90.10. 1 hit.
InterProiIPR001211. PLipase_A2.
IPR033112. PLipase_A2_Asp_AS.
IPR016090. PLipase_A2_dom.
IPR033113. PLipase_A2_His_AS.
[Graphical view]
PANTHERiPTHR11716. PTHR11716. 1 hit.
PfamiPF00068. Phospholip_A2_1. 1 hit.
[Graphical view]
PRINTSiPR00389. PHPHLIPASEA2.
SMARTiSM00085. PA2c. 1 hit.
[Graphical view]
SUPFAMiSSF48619. SSF48619. 1 hit.
PROSITEiPS00119. PA2_ASP. 1 hit.
PS00118. PA2_HIS. 1 hit.
[Graphical view]
ProtoNetiSearch...

Publicationsi

  1. "Analysis of Bothrops jararacussu venomous gland transcriptome focusing on structural and functional aspects: I -- gene expression profile of highly expressed phospholipases A2."
    Kashima S., Roberto P.G., Soares A.M., Astolfi-Filho S., Pereira J.O., Giuliati S., Faria M. Jr., Xavier M.A.S., Fontes M.R.M., Giglio J.R., Franca S.C.
    Biochimie 86:211-219(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA].
    Tissue: Venom gland.
  2. "Bothrops jararacussu myotoxic phospholipase A2-like mRNA."
    Hayashi M.A.F., Queiroz G.P., Radis-Baptista G., Yamane T., Camargo A.C.M.
    Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases
    Cited for: NUCLEOTIDE SEQUENCE [MRNA].
    Tissue: Venom gland.
  3. Cited for: PROTEIN SEQUENCE OF 17-137.
    Tissue: Venom.
  4. "Sequence of a cDNA encoding bothropstoxin I, a myotoxin from the venom of Bothrops jararacussu."
    Ward R.J., Monesi N., Arni R.K., Larson R.E., Paco-Larson M.L.
    Gene 156:305-306(1995) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 17-137.
    Tissue: Venom gland.
  5. Ward R.J.
    Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases
    Cited for: SEQUENCE REVISION.
  6. "Assignment of the disulfide bridges in bothropstoxin-I, a myonecrotic Lys49 PLA2 homolog from Bothrops jararacussu snake venom."
    Cintra A.C.O., Sampaio S.V., Raghuvir A.K., Giglio J.R.
    J. Protein Chem. 20:377-382(2001) [PubMed] [Europe PMC] [Abstract]
    Cited for: PROTEIN SEQUENCE OF 17-137, DISULFIDE BONDS.
    Tissue: Venom.
  7. "Fractionation of Bothrops jararacussu snake venom: partial chemical characterization and biological activity of bothropstoxin."
    Homsi-Brandeburgo M.I., Queiroz L.S., Santo-Neto H., Rodrigues-Simioni L., Giglio J.R.
    Toxicon 26:615-627(1988) [PubMed] [Europe PMC] [Abstract]
    Cited for: PROTEIN SEQUENCE OF 17-26, FUNCTION, LETHAL DOSE.
  8. "Myotoxic phospholipases A(2) in bothrops snake venoms: effect of chemical modifications on the enzymatic and pharmacological properties of bothropstoxins from Bothrops jararacussu."
    Andriao-Escarso S.H., Soares A.M., Rodrigues V.M., Angulo Y., Diaz C., Lomonte B., Gutierrez J.M., Giglio J.R.
    Biochimie 82:755-763(2000) [PubMed] [Europe PMC] [Abstract]
    Cited for: FUNCTION, BIOASSAY, LETHAL DOSE.
    Tissue: Venom.
  9. "Active-site mutagenesis of a Lys49-phospholipase A2: biological and membrane-disrupting activities in the absence of catalysis."
    Ward R.J., Chioato L., de Oliveira A.H., Ruller R., Sa J.M.
    Biochem. J. 362:89-96(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: FUNCTION, BIOASSAY, LACK OF CATALYTIC ACTIVITY, MUTAGENESIS OF HIS-63; LYS-64 AND LYS-128.
  10. "Distinct sites for myotoxic and membrane-damaging activities in the C-terminal region of a Lys49-phospholipase A2."
    Chioato L., De Oliveira A.H., Ruller R., Sa J.M., Ward R.J.
    Biochem. J. 366:971-976(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: FUNCTION, BIOASSAY, MUTAGENESIS OF LYS-121; LYS-122; TYR-123; ARG-124; TYR-125; LYS-128; PHE-130; LYS-132 AND LYS-133.
  11. "Mapping of the structural determinants of artificial and biological membrane damaging activities of a Lys49 phospholipase A2 by scanning alanine mutagenesis."
    Chioato L., Aragao E.A., Lopes Ferreira T., Medeiros A.I., Faccioli L.H., Ward R.J.
    Biochim. Biophys. Acta 1768:1247-1257(2007) [PubMed] [Europe PMC] [Abstract]
    Cited for: FUNCTION, BIOASSAY, MUTAGENESIS OF LYS-23; LYS-31; LYS-51; PRO-52; LYS-53; ASP-54; ARG-58; TYR-61; HIS-63; LYS-68; LYS-69; 72-LYS-ARG-73; LYS-87; GLU-93; LYS-99; LYS-106; THR-118; ASN-120; LYS-121; LYS-122; TYR-123; ARG-124; TYR-125; HIS-126; LEU-127; LYS-128; PHE-130; LYS-132 AND LYS-133.
  12. "Permeabilization of E. coli K12 inner and outer membranes by bothropstoxin-I, a Lys49 phospholipase A2 from Bothrops jararacussu."
    Aragao E.A., Chioato L., Ward R.J.
    Toxicon 51:538-546(2008) [PubMed] [Europe PMC] [Abstract]
    Cited for: FUNCTION, MUTAGENESIS OF HIS-63; LYS-121; TYR-123; ARG-124; LYS-128; PHE-130 AND LYS-133.
    Tissue: Venom.
  13. "Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues."
    Murakami M.T., Vicoti M.M., Abrego J.R.B., Lourenzoni M.R., Cintra A.C.O., Arruda E.Z., Tomaz M.A., Melo P.A., Arni R.K.
    Toxicon 49:378-387(2007) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 17-137, FUNCTION, SUBUNIT, DISULFIDE BONDS.
    Tissue: Venom.
  14. "Comparative structural studies on Lys49-phospholipases A(2) from Bothrops genus reveal their myotoxic site."
    dos Santos J.I., Soares A.M., Fontes M.R.
    J. Struct. Biol. 167:106-116(2009) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 17-137 IN COMPLEX WITH ALPHA-TOCOPHEROL, SUBUNIT, DISULFIDE BONDS.
  15. "Comparison between apo and complexed structures of bothropstoxin-I reveals the role of Lys122 and Ca(2+)-binding loop region for the catalytically inactive Lys49-PLA(2)s."
    Fernandes C.A., Marchi-Salvador D.P., Salvador G.M., Silva M.C., Costa T.R., Soares A.M., Fontes M.R.
    J. Struct. Biol. 171:31-43(2010) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) OF 17-137 ALONE; IN COMPLEX WITH THE PLA2 INHIBITOR BROMOPHENACYL BROMIDE (BPB) AND IN COMPLEX WITH POLYETHYLENE GLYCOL (PEG4), SUBUNIT, DISULFIDE BONDS.
    Tissue: Venom.

Entry informationi

Entry nameiPA2B1_BOTJR
AccessioniPrimary (citable) accession number: Q90249
Secondary accession number(s): Q7LZ25, Q804D7
Entry historyi
Integrated into UniProtKB/Swiss-Prot: December 5, 2001
Last sequence update: July 22, 2008
Last modified: May 11, 2016
This is version 95 of the entry and version 3 of the sequence. [Complete history]
Entry statusiReviewed (UniProtKB/Swiss-Prot)
Annotation programAnimal Toxin Annotation Program
Annotation programChordata Protein Annotation Program

Miscellaneousi

Caution

Does not bind calcium as one of the calcium-binding ligands is lost (Asp->Lys in position 64, which corresponds to 'Lys-49' in the current nomenclature). However, the hydrolytic activity is not restored by the mutant containing an Asp-64, indicating that other residues play a key role in hydrolytic activity.Curated

Keywords - Technical termi

3D-structure, Direct protein sequencing

Documents

  1. PDB cross-references
    Index of Protein Data Bank (PDB) cross-references
  2. SIMILARITY comments
    Index of protein domains and families

Similar proteinsi

Links to similar proteins from the UniProt Reference Clusters (UniRef) at 100%, 90% and 50% sequence identity:
100%UniRef100 combines identical sequences and sub-fragments with 11 or more residues from any organism into one UniRef entry.
90%UniRef90 is built by clustering UniRef100 sequences that have at least 90% sequence identity to, and 80% overlap with, the longest sequence (a.k.a seed sequence).
50%UniRef50 is built by clustering UniRef90 seed sequences that have at least 50% sequence identity to, and 80% overlap with, the longest sequence in the cluster.